Unicycive Therapeutics Inc
NASDAQ:UNCY
Unicycive Therapeutics Inc
NASDAQ:UNCY
Price:
6.33
USD
-2.76%
Market Cap:
$136m
Relative Value
There is not enough data to reliably calculate the relative value of UNCY.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
UNCY
Relative Value
Base Case
Not Available
Multiples Across Competitors
UNCY Competitors Multiples
Unicycive Therapeutics Inc Competitors
Unicycive Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Unicycive Therapeutics Inc
NASDAQ:UNCY
|
133.2m USD | 0 | -3.5 | -2.8 | -2.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
382.9B USD | 6.5 | 164.7 | 16 | 22.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
196.8B USD | 5.5 | 28.1 | 19.9 | 19.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
185.2B USD | 6.4 | 22.9 | 15.5 | 15.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.4B USD | 10 | 31.9 | 23.4 | 24.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.9B USD | 5.7 | 18.1 | 15.3 | 17.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
87.9B AUD | 3.9 | 20.4 | 13.6 | 17 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.9B EUR | 14.5 | 34 | 58.1 | 59.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
